key: cord-0871585-wb1apvn2
authors: Chopra, diti; Sivaraman, Karthik; Radhakrishnan, Raghu; Balakrishnan, Dhanasekar; Narayana, Aparna
title: Can povidone Iodine gargle/mouthrinse inactivate SARS-CoV-2 and decrease the risk of nosocomial and community transmission during the COVID-19 pandemic? An evidence-based update
date: 2021-03-15
journal: Jpn Dent Sci Rev
DOI: 10.1016/j.jdsr.2021.03.001
sha: 60a35f32318a7ba9933458822eedb5d1ce1c037e
doc_id: 871585
cord_uid: wb1apvn2

The Coronavirus disease in 2019 (COVID-19), also referred to as the novel ‘CoV19 (nCov19)’ is caused by a new coronavirus strain similar to Severe Acute Respiratory Syndrome (SARS-CoV-2). SARS-CoV-2 spreads via respiratory droplets, saliva, or direct contact. Therefore it is important to control the viral load in the saliva and respiratory secretions. One of the most simple and cost-effective measures that can be adopted by the public and healthcare professionals to prevent cross-contamination and community transmission, is the implementation of effective oral and throat hygiene. Recent evidence has confirmed 0.5% PVP-I mouthrinse/gargle for 30 seconds can reduce SARS-CoV-2 virus infectivity to below detectable levels. PVP-I can even interrupt SARS-CoV-2 attachment to oral and nasopharyngeal tissues and lower the viral particles in the saliva and respiratory droplets. Thus the use of PVP-I mouthrinse as prophylactic measures has been advocated across the globe to reduce disease transmission. Although the efficacy of PVP-I against SARS-CoV-2 is proven, no review articles have yet discussed the evidence and mechanisms of PVP-I against the SARS-CoV-2. Thus, this paper highlights the rationale, safety, recommendations, and dosage of PVP-I gargle/mouthrinse as an effective method to decrease the viral loads during the pressing times of COVID-19.

The Coronavirus disease in 2019 , also referred to as the novel 'CoV19 (nCov19)' is caused by a new coronavirus strain of SARS-CoV-2 1 . SARS-CoV-2 was confirmed as a 'Public Health Emergency of International Concern (PHEIC)', warranting a coordinated international response to fight this unprecedented public health crisis in January 2020. As of 26 th September 2020, SARS-CoV-2 has affected more than 32,765,274 individuals worldwide, with nearly 993,464 deaths.

SARS-CoV-2 is a single-stranded RNA beta-coronavirus, which belongs to the 'Sarbeco virus subgenus of the Coronaviridae family. The SARS-CoV-2 is 89% identical to batSARS-like-CoVZXC 21 and 82% equal to human SARS-CoV in its genomic sequence 2 . SARS-CoV-2 is a zoonotic disease similar to Middle East Respiratory Syndrome Coronavirus (MERS-CoV). and SARS-CoV.

The SARS-CoV-2 infection may have initiated from the wet market in Wuhan, Hubei district, China 1 . The virus is believed to reside in the Chinese horseshoe bats (Rhinolophus sinicus) 2,3 with Malayan pangolins (Manis javanica) as the most likely intermediate host 4, 5 . A recent paper evaluating the probable origin of SARS-CoV-2 suggested that "it could have originated either by natural selection in an animal following zoonotic transfer or by natural selection in human following zoonotic transfer" 6 . Evidence suggests that COVID-19 emerged from a single animal to human transmission, with subsequent genetic mutations resulting in rapid and continued humanto-human spread 2, 7 . Human to human transmission is known to occur via respiratory droplets and contact routes primarily 3, 4, 8 . However, researchers have indicated that the risk of fecal to the oral transmission cannot be negated, since SARS-CoV-2 has been identified in the stools of patients 9 .

With researchers intensifying their efforts to develop an effective vaccine to treat J o u r n a l P r e -p r o o f patients, all efforts are being made to reduce the spread of the viral particles and mitigate the spread of infection.

It is obligatory to follow effective social distancing measures and isolate both the symptomatic and asymptomatic COVID-19 patients to reduce the spread of infection. Rational use of adequate personal protective equipment (PPE) and personal hygiene in both hospitals and clinics, as well as appropriate biomedical waste management, are also essential to keep the healthcare workers from getting exposed to the viral particles of SARS-CoV-2. In addition to these non-pharmaceutical interventions, a crucial factor that could necessarily slow down the spread of the virus is scrupulous maintenance of oral hygiene using a virucidal mouth rinse/gargle. Dentists are at higher risk of acquiring SARS-CoV-2, due to proximity with the oral cavity. Therefore dentists must adopt suitable preventive measures to lower the load of SAR-CoV-2 in the oral cavity. Preoperative mouth rinsing with a suitable virucidal mouthwash is considered as the main preventive option to control the viral load in the saliva and the aerosol during and after any dental procedure.

Based on available evidence in the literature, Povidone-iodine (PVP-I), iodine with the watersoluble polymer polyvinylpyrrolidone is proven to be effective against coronavirus 10, 11 . Oral and nasal decontamination by using PVP-I can reduce 'the amount of virus particle aerosolization before it reaches barriers, surfaces, and fomites 12, 13 . Considering the complex dynamics involved, the paper explains the mechanisms and importance of the PVP-I gargle as a viable prophylactic measure to lower the viral loads in the oral and oropharyngeal region to interrupt the progression of the COVID-19 infection. The paper also discusses the current evidence that supports the virucidal properties of PVI-P on the novel SAR-CoV-2 and its role in preventing the spread of infection during the COVID-19 pandemic. The paper is timely and is of paramount importance to (Table 1 and Table 2 ). However, there are a lot of clinical trials and ongoing studies trying to confirm the efficacy of PVP-I against SARS-CoV2 (Supplementary Table) . Based on the in-vitro studies, the ADA interim guidelines for minimizing the risk of COVID-19 transmission suggest the preprocedural oral rinsing with 1.5% hydrogen peroxide (commercially available in the United States) or 0.2% PVP-I (not commercially available in the United States) [14] [15] [16] [17] [18] [19] [20] . The CDC recommends preprocedural rinsing with antimicrobial rinses such as chlorhexidine gluconate, essential oils, PVP-I, or cetylpyridinium chloride. PVP-I is safe for use in the oral and nasal cavities at concentrations up to 1.25% 21 . In the absence of any commercially available preparations for routine dental use during the COVID19 pandemic, it is advised to dilute 10% PVP-I by 1:20 and mix 0.5cc of the diluted PVP-I solution with 9.5cc of sterile saline or sterile water for routine clinical use [18] [19] [20] [21] [22] . Bidra et al. (2020) recommend the regular use of the diluted form of 0.5% PVP-I oral rinse to decrease the risk of nosocomial transmission associated with viral shedding from asymptomatic individuals. 17, 18 It is also advised to frequently use PVP-I oral and nasal spray in hospital settings with inadequate PPEs (Table 1) . At this concentration, iodine absorption is minimal and is below the total daily iodine intake for a healthy adult of 150 µg 22 .

The current evidence supports the virucidal properties of PVI-P against the novel SAR-CoV-2.

The preoperative use of PVP-I mouthrinse/gargle is important in preventing the spread of infection during the COVID-19 pandemic. The rationale, virucidal properties, dosage, and studies proving the efficacy of PVP-I during the COVID-19 pandemic is summarized as follows:

Since the oral, nasal, and respiratory tract is strongly interconnected, the importance of maintaining good oral hygiene by gargling and rinsing with an antiseptic mouth rinse during the respiratory tract infections like SARS-CoV-2 is crucial. Studies have shown various components of the oral cavity, such as gingival crevices, buccal mucosa, tongue, tonsils, palate, micro-cracks on the tooth surface, provide a perfect niche for viral particles in patients suffering from viral respiratory infections 12, 13 . Moreover, the oral biofilm-induced periodontal inflammation is also linked with the development of lower respiratory tract infection that can trigger the onset of ventilatorassociated pneumonia (VAP) [22] [23] [24] [25] [26] [27] .

Many systematic reviews and meta-analyses have confirmed the importance of good oral hygiene and the use of chemical antiseptic agents to prevent respiratory disorders and nosocomial infection 25-30 . Additionally, oral prophylaxis is also confirmed to have a critical role in regulating the SARS-CoV-2 pandemic, as intact oral mucosa circumvents the virus-invade-host theory. The receptor-binding domain of SARS-CoV-2 has an affinity for binding to human Angiotensin-Converting Enzyme 2 (ACE2) receptors 6, 7, 31, 32 . The ACE2 receptors are prevalent in the lungs, oral tissue, and salivary glands, making them a potential site for invasion [29] [30] [31] [32] . The oral cavity is J o u r n a l P r e -p r o o f 'identified as a high-risk infectivity site' with saliva being a primary mode of transmission of viral particles and a potential source of community-wide spread of infection [29] [30] [31] .

In patients with severe COVID-19, saliva ejected from the salivary gland ducts has shown to contain 2019nCoV nucleic acid, possibly serving as an ideal candidate for non-invasive diagnostic testing [32] [33] [34] [35] [36] [37] [38] . The viral particles from the infectious respiratory fluids and salivary droplets bring about a short-distance transmission during breathing, talking, coughing, or sneezing 32, 33 . Large salivary droplets, with a diameter of more than 60 μm, usually settle down quickly, limiting the transmission to only those persons who are near the source 34 . However, smaller droplets (diameter ≤ 60 μm), which evaporate and form droplet nuclei of diameter < 10 μm, have the capacity for long-distance aerosol transmission 31 . With an estimated expulsion of 40,000 saliva droplets generated with each sneeze, it is essential to reduce the salivary viral load [34] [35] [36] . Studies have confirmed that the viral load in the saliva of an infected COVID-19 at the time of hospitalization is as high as 1·2×10 8 infective copies/ml 37 . Considering the fatality rate of COVID-19 ranging between 0.39% and 4.05%, the risk of transmission from infected hospitalized individuals to healthy family members, caretakers, healthcare professionals, and other patients visiting the hospital is high 37, 11 . The risk of transmission is also increased for hospitalized patients requiring procedures such as non-invasive ventilation, intubation, and suction, which generate bioaerosol and result in nosocomial transmission among healthcare workers 11 . In a retrospective study in Wuhan on hospitalized patients having novel corona virus-infected pneumonia (NCIP), approximately 40% of cases were found to have a hospital-associated transmission as the purported mechanism of acquiring infection 38 shown to be beneficial for healthcare professionals, mainly dentists and otolaryngologists, who are at an increased risk of exposure as they contact the oral and pharyngeal mucosa directly during diagnosis and treatment. During the procedure, viral particles get aerosolized and remain airborne for three to four hours, contaminating multiple surfaces in the surrounding area. Thus dentists need to take utmost precaution and reduce the viral load in the saliva and oropharyngeal region.

The importance of maintaining oral hygiene practices such as regular tooth brushing and denture cleaning can also reduce the number of febrile days and risk of pneumonia in frail older people.

PVP-I gargle/mouth rinse/spray has been shown to reduce the incidence of nosocomial pneumonia and its attendant complications and mortality by nearly 40% [40] [41] [42] [43] . Professional oral care, along with the diligent use of PVP-I, can reduce the levels of potential respiratory pathogens and the incidence of aspiration pneumonia 44 . Therefore, repeated use of PVP-I is indicated for symptomatic patients infected with SARS-CoV-2, particularly in the first one to two weeks after the beginning of signs J o u r n a l P r e -p r o o f and symptoms, as the viral load in oral and oropharyngeal secretion is the highest during that time 29 . It is also essential that PVP-I is used in asymptomatic patients, as these individuals may potentially spread the infection to both healthcare professionals and the community 2,19,45 . 

The habit of gargling and rinsing with undiluted PVP-I (10-15 mL) for 30 seconds is a standard regimen to prevent sore throat 17 and for antiseptic prophylaxis before, during, or after surgery.

However, extended rinsing with an appropriate dilution of PVP-I, for more than 2 minutes, up to four times a day, is advocated to reduce the incidence of airborne respiratory infections such as avian flu, SARS, swine flu 33, 34 . The use of PVP-I mouthrinse has been recommended as a preventive strategy to effectively inactivate the viral load in the oral and oral pharyngeal region, infected with SARS-CoV-2 6, 11 . Gargling with PVP-I has been recommended by the Respiratory Society in Japan for the prevention and treatment of hospital/ community-acquired respiratory infections. 55 These recommendations are based on previous studies where PVP-I gargle and throat spray, revealed virucidal properties against both the low pathogenic (H5N3, H7N7, and H9N2) strains of avian influenza A and highly pathogenic (H5N1) viruses 55 (Table 1) . A recent letter by Challacombe et al., 2020 recommended the use of 0.5% PVP-I solution (9 ml) as a mouthwash for 30 seconds followed by an additional 30 seconds of gargling before spitting 63 . In the United Kingdom, patients who are conscious and are infected with COVID19 or persons under examination for COVID19 were given 0.5% PVP-I rinse (0.3 mL) in both the nostril and 9 mL in the oral cavity before any procedures. 13, 48, 61 In unconscious patients, the application of 2 mL of PVP-I onto the mucosal surfaces of the oral cavity was advised.

J o u r n a l P r e -p r o o f 0·5% (5 mg/ml) of PVP-I can be applied to oral, nasal, and oropharyngeal mucosa of patients with presumed/confirmed COVID-19 patients or healthcare personnel in close contact to prevent the risk of cross-contamination 11 . PVP-I mouth rinses, every 2-3, or about 4 times a day, is recommended for healthcare workers exposed to infected patients 11 . Another protocol in Pittsburgh recommended application of '240 ml of 0.4% PVP-I in the nasal cavity via sinus rinse delivery bottle and 10 mL of 0.5% PVP-I oral rinse every 2-3 hours, four times in a day, in patients diagnosed with COVID-19, under investigation or before high-risk procedures' 64 . The author also recommended this regime for health care workers before examining or treating suspected or diagnosed COVID-19 patients, performing high-risk procedures, and in a setting with underresourced PPE. PVP-I is also a part of the anesthesia guideline for operative/surgical room care during the COVID-19 pandemic and recommends the use of nasal PVP-I within one hour of incision for all patients [63] [64] [65] . Most of these protocols apply to both symptomatic and asymptomatic patients.

To prevent cross-contamination among dentists, the 'American Dental Association (ADA)' has approved the use of 0.2% of PVP-I mouthwash before all dental procedures during the COVID19 pandemic. Since no commercial preparations of PVP-I for routine dental use is available, dilute the 10% PVP-I (1:20), using 0.5cc of 10% PVP-I and 9.5cc of sterile water or saline, for clinical application [11] [12] [13] [14] . Parhar et al., (2020) stated that "until confirmatory studies are performed, it is best to dilute the PVP-I with saline (typically 7.5%) in a ratio of 1:3, to attain a concentration of less than 2%. 16 iodine can be safely administered for up to five months in the nasal cavity, and six months in the oral cavity 63 . In an in-vitro study assessing the safety of PVP-I on the oral mucosa of rats, apoptosis of cells occurred at a concentration of 1 ×10 2 mM for one day 64 . An in vivo study confirmed that prolonged use of 1% to 1.25% PVP-I gargle did not irritate mucosa or result in any adverse effects of up to 28 months. Povidone-iodine gargle did not stain teeth or cause a change in gustatory function [65] [66] [67] . However, there have been reports of inadvertent aspiration pneumonia in patients while gargling with PVP-I solution at 0.25% to 10% 66 . Although a small amount of iodine is systemically absorbed from the mucosa, thyroid function is not commonly affected. However, an increase in the serum thyroid-stimulating hormone concentration has been noted in individuals with prolonged PVP-I treatment (24 weeks) 41--48 . Under these circumstances, it is advisable to have a 3-week interval to allow the serum TSH levels to stabilize. PVP-I should be avoided in patients with hyperthyroidism, thyroid dysfunction states, pregnancy, and lactation [48] [49] [50] [51] . Allergy to PVP-I is also extremely rare, with a prevalence rate of 0·4% 10 .

Oral hygiene intervention, along with the gargling/mouthwash with an antiseptic having virucidal properties is imperative during this pandemic of COVID 19. Based on the Occupational Safety and Health Administration guidelines, PVP-I is safe to use as a mouth rinse, and the existing invitro studies and patient-based clinical trials confirm its virucidal property against SARS-CoV-2.

In vitro studies have confirmed that 0.5% PVP-I is effective in reducing SARS-CoV-2 in the nasal cavity, nasopharynx, oral cavity, and oropharynx. Since vaccines against SARS-CoV-2 are being rolled and administered globally, the use of PVP-I gargle/ mouthwash as a simple, inexpensive, and safe adjunct should be used to reduce the risk of cross-transmission of SARS-CoV-2 viral particles to the community and healthcare professionals. Routine PVP-I gargling/mouthwash/nasal spray can be implemented for all hospitalized and non-hospitalized, symptomatic, and asymptomatic patients infected with SARS-CoV-2 to reduce the viral load. It is equally essential for healthcare professionals (dentists, dental assistants, dental technicians), isolated and quarantined individuals, frequent travelers to use PVP-I mouthrinse to minimize the risk of crossinfection in both the hospital and non-hospital settings. A timely prophylactic oral hygiene regimen using appropriate gargle/mouth rinse, and promoting awareness of the harmful outcomes of poor oral health, may significantly improve the health among vulnerable patients and bridge the gap between oral and general health during the COVID19 pandemic. 

The Novel Coronavirus Originating in Wuhan, China: Challenges for Global Health Governance

A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster

Community Transmission of Severe Acute Respiratory Syndrome Coronavirus 2

Emerging novel coronavirus (2019-nCoV)-current scenario, evolutionary perspective based on genome analysis and recent developments

The proximal origin of SARS-CoV-2

Novel Coronavirus-Important Information for Clinicians

Respiratory virus RNA is detectable in droplet particles

First Case of 2019 Novel Coronavirus in the United States

Infectious Disease Management and Control with Povidone Iodine

The Use of Povidone Iodine Nasal Spray and Mouthwash During the Current COVID-19 Pandemic May Protect Healthcare Workers and Reduce Cross Infection

Systematic review of the association between respiratory diseases and oral health

Efficacy of Povidone-Iodine Nasal and Oral Antiseptic Preparations Against Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2)

Perioperative COVID-19 Defense: An Evidence-Based Approach for Optimization of Infection Control and Operating Room Management

SARS-CoV-2 Viral Inactivation Using Low Dose Povidone-Iodine Oral Rinse -Immediate Application for the Prosthodontic Practice

Topical preparations to reduce SARS-CoV-2 aerosolization in head and neck mucosal surgery

Rapid In-Vitro Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Using

Povidone-Iodine Oral Antiseptic Rinse

Comparison of In Vitro Inactivation of SARS CoV-2 with Hydrogen Peroxide and Povidone-Iodine Oral Antiseptic Rinses

Virucidal Efficacy of Different Oral Rinses Against Severe Acute Respiratory Syndrome Coronavirus 2

The role of oral microbial colonization in ventilator-associated pneumonia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod

Povidone-iodine to prevent mucositis in patients during antineoplastic radiochemotherapy

Povidone-Iodine Use in Sinonasal and Oral Cavities: A Review of Safety in the COVID-19 Era

Oral biofilms, periodontitis, and pulmonary infections

Evidence summary: the relationship between oral health and pulmonary disease

Oral hygiene care for critically ill patients to prevent ventilator-associated pneumonia

Oral hygiene in patients with chronic obstructive pulmonary disease: a scoping review protocol

Oral care measures for preventing nursing home-acquired pneumonia

Transmission routes of 2019-nCoV and controls in dental practice

Consistent detection of 2019 novel coronavirus in saliva

Potential interventions for novel coronavirus in China: A systematic review

Saliva: potential diagnostic value and transmission of 2019-nCoV

SARScov-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Guidelines for infection control in dental health care settings--2003

Factors involved in the aerosol transmission of infection and control of ventilation in healthcare premises

Characterization of infectious aerosols in health care facilities: an aid to effective engineering controls and preventive strategies

Inhaling to mitigate exhaled bioaerosols

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany

Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travelers from Wuhan, China

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Children and Adolescents: A Systematic Review

Potential associations between chronic respiratory disease and disease: analysis of National Health and Nutrition Examination Survey III

Oral health care and aspiration pneumonia in frail older people: a systematic literature review

SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients

Effect of povidone-iodine on herpesvirus type 2, in vitro

Inactivation of human viruses by povidone-iodine in comparison with other antiseptics

Practical use of povidoneiodine antiseptic in the maintenance of oral health and in the prevention and treatment of common oropharyngeal infections

Molecular effects of povidone-iodine on relevant microorganisms: an electron-microscopic and biochemical study

Antiinflammatory properties of a liposomal hydrogel with povidone-iodine (Repithel) for wound healing in vitro

Virucidal activity and cytotoxicity of the liposomal formulation of povidone-iodine

Mechanisms of the action of povidone-iodine against human and avian influenza A viruses: its effects on hemagglutination and sialidase activities

Potential Role of Oral Rinses Targeting the Viral Lipid Envelope in SARS-CoV-2 Infection. Function (Oxf)

Prevention of hospital-acquired pneumonia (strategies for prevention of hospitalacquired infections)

Outbreak of highly pathogenic avian influenza in Japan and antiinfluenza virus activity of povidone-iodine products

Inactivation of SARS coronavirus by means of povidoneiodine, physical conditions, and chemical reagents

Inactivation of SARS coronavirus by means of povidoneiodine, physical conditions and chemical reagents

In Vitro Bactericidal and Virucidal Efficacy of Povidone-Iodine Gargle / Mouthwash Against Respiratory and Oral Tract Pathogens

Prevention of respiratory infections by povidone-iodine gargle

In-Vivo Toxicity Studies and In-Vitro Inactivation of SARS-CoV-2 by Povidone-iodine In-situ Gel Forming Formulations

Is povidone iodine mouthwash effective against SARS-CoV-2? First in vivo tests

Stability of SARS-CoV-2 in different environmental conditions

Povidone-iodine

Personal Protective Equipment " for frontline providers exposed in high-risk head and neck and

Protection at Portal of Entry (PPE) with Povidone Iodine for COVID-19

Povidone-iodine-induced cell death in cultured human epithelial HeLa cells and rat oral mucosal tissue

The use of Betadine antiseptic in the treatment of oral surgical, parodontological and oral mucosal diseases

Pneumonia due to aspiration of povidone iodine after preoperative disinfection of the oral cavity

Povidone-Iodine Solution: A Potential Antiseptic to Minimize the Risk of COVID-19? A Narrative Review

Potential mouth rinses and nasal sprays that reduce SARS-CoV-2 viral load: What we know so far

PVP-I resulted in a significant drop in viral load, which remained for at least 3 hours.Lamas et al. [53]